A Study to Assess Safety, Tolerability and Pharmacokinetics of Ceftaroline in Healthy Subjects
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- David Melnick, MD
AstraZeneca PharmaceuticalsC2C-7161800 Concord PikePO. Box 15437Wilmington De 19850-5437
Study Director - Elizabeth Tranter, MBCHB MRCP
Hammersmith Medicines Cumberland Avenue London NW10 7EW UK
Principal Investigator - Mirjana Kujacic, MD
AstraZeneca Research and DevelopmentSE-431 83 MolndalSweden
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Research Site
London, United Kingdom
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jul 2012
- Primary completion
- 30 Nov 2012
- Completion
- 30 Nov 2012
- Last update posted
- 5 Sept 2017
- Registered enrollment
- 41
- Registry id
- NCT01612507
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.